Free Trial
NASDAQ:TRVI

Trevi Therapeutics Q1 2025 Earnings Report

Trevi Therapeutics logo
$6.90 -0.09 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$6.74 -0.17 (-2.39%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Trevi Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Trevi Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Trevi Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Trevi Therapeutics Earnings Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
Trevi Therapeutics management to meet virtually with B. Riley
Trevi Therapeutics management to meet with Cantor Fitzgerald
See More Trevi Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevi Therapeutics and other key companies, straight to your email.

About Trevi Therapeutics

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

View Trevi Therapeutics Profile

More Earnings Resources from MarketBeat